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There's more to being right- or ieft-handed than meets the eye. Researchers 
at Boston University School of Medicine's Aphasia Research Center have 
discovered that one's hand preference affects speech patterns after brain 
injury. See story on page 3. 
Vaccine to protect 
against some forms 
of cancer appears 
effective in mice 
One day humans may be immunized 
against cancers caused by certain 
chemicals in the environment, 
thanks to research being conducted 
at Boston University School of 
Medicine. 
A BUSM research team headed by 
Frederick L. Moolten, M.D., has been 
working for four years to develop a 
vaccine against cancers caused by 
chemical carcinogens. The 
researchers already have success-
fully vaccinated laboratory mice 
against a particular group of chemi-
cals by injecting the mice with a 
modified version of the chemicals. 
This test showed half the number of 
tumors in immunized mice as there 
were in those unimmunized mice 
exposed to the same carcinogens. 
The researchers hope that, with 
further research, such a vaccine 
might eventually be available for 
human use. 
"For a long time, it has been 
standard practice to use immuniza-
tion as a public-health measure to 
protect against toxic substances 
produced by bacteria, such as teta-
nus or diptheria toxin. Our research 
indicates that similar protection 
might eventually be feasible for 
humans to protect them against car-
cinogens in the environment," said 
Moolten, an associate professor of 
continued on page 2 
BUSM cancer researcher Frederick L. Moolten, M.D., examines tumors on laboratory 
mice that are unusually sensitive to carcinogens. (Photo by Bradford F. Herzog) 
New tool to diagnose, treat diabetic 
retinopathy emerging from BUSM study 
Each year in the United States, 
approximately one out of four peo-
ple suffering from diabetes mellitus 
will be affected by diabetic retino-
pathy, a complication of diabetes 
that in 1982 will cause more new 
cases of blindness among Ameri-
cans than any other disorder. 
Researchers at Boston University 
School of Medicine have developed 
a unique noninvasive procedure to 
diagnose diabetic retinopathy that 
not only provides a tool for early 
detection, but could significantly 
improve the current treatment 
method. 
The new technique, developed at 
BUSM over a three-year period, has 
been successfully tested in animals 
and is now ready to be applied to 
humans. It employs a highly devel-
oped optical scanning system that 
may enable ophthalmologists to min-
imize or even prevent the frequently 
tragic results of diabetic retinopathy. 
Diabetes affects an estimated 200 
million people of all ages throughout 
continued on page 5 
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Cancer vaccine... 
continued from page 1 
microbiology at BUSM and a 
member of the School's Hubert H. 
Humphrey Cancer Research Center 
staff. 
Moolten's work has focused on 
developing a vaccine against a fam-
ily of cancer-causing chemicals 
called polycyclic aromatic hydrocar-
bons (PAHs)~chemicals commonly 
found in cigarette smoke, automo-
bile exhaust and broiled and smoked 
foods. "Most of us are exposed daily 
to small quantities of these carcino-
gens in the environment, and it is 
likely that these compounds con-
tribute to the incidence of human 
cancer," Moolten said. 
Working in conjunction with Eli-
ahu Boger, Ph.D., an adjunct profes-
sor of chemistry at Boston College, 
Moolten created an antigen (a sub-
stance that when introduced into the 
system produces an antibody that 
can bind the substance and perhaps 
neutralize it) from a synthetic, non-
carcinogenic derivative of PAH, 
abbreviated as 5-FMBAAA-BSA. 
"When we immunized mice and 
guinea pigs with this antigen, we 
found that antibodies were produced 
that could protect living cells in 
tissue culture from the effects of the 
carcinogenic PAHs," said Moolten, 
who is assisted in his work by Alan 
J. Weiss, a graduate student in the 
Department of Biochemistry at 
BUSM. The researchers, whose work 
is supported by the National Cancer 
Institute of the National Institutes of 
Health, also found that when the 
laboratory animals were exposed to 
carcinogens, these antibodies would 
intercept the carcinogen molecule 
within the animal and the chemicals 
would be excreted from the body. 
When the researchers induced 
antibodies in the respiratory tracts of 
the animals, and then exposed them 
to the PAH carcinogen benzo(a)py-
rene, a component of tobacco 
smoke and polluted air, they found 
that the immunization reduced the 
quantity of the carcinogens taken up 
into the respiratory tissues. "The 
quantity of the carcinogen that could 
be intercepted suggested that the 
immunization might be sufficient to 
cope with most types of human 
exposure to inhaled PAH carcino-
gens," Moolten stated. 
In a 40-week study of approxi-
mately 400 mice repeatedly exposed 
to skin applications of small doses of 
a carcinogenic PAH, dimethylbenz(a)-
anthracene, the research team 
found that the immunized mice had 
half the skin tumors as mice in a 
control group that did not receive 
the immunization. 
"The results suggest that, when 
mice are exposed to a carcinogen at 
doses low enough to approach 
environmental levels, immunization 
against the carcinogen can provide 
specific protection," Moolten said. 
The research team currently is 
repeating the experiments, measur-
ing the effects of different doses of 
the antigen and using a breed of 
mice known to be unusually sensi-
tive to carcinogens "to get quicker 
and more precise results." They also 
are conducting experiments to see if 
other antigens offer protection 
against other groups of carcinogens, 
and are studying the body's immune 
system to define the types of cellular 
response mechanisms that are 
responsible for this protection. 
"We are slowly progressing," 
Moolten said. The concept of 
immunity to carcinogens was first 
examined in the 1930s by Dr. Hugh 
Creech, a Philadelphia cancer 
researcher, who started studying the 
ability to induce immune response 
with PAHs, Moolten said. The tech-
nology was not available at that time, 
however, to fully develop the 
hypothesis. 
"To use the vaccine on humans is 
our ultimate goal, but it's at least 
several years away—perhaps a 
decade or more," Moolten stated. 
"First, we have to prove it will work 
in a variety of experimental condi-
tions, and it has to undergo rigorous 
safety tests. We have to be able to 
show it to be effective against car-
cinogens known to cause human 
cancer. A lot more information is 
needed about which carcinogens are 
hazardous to humans." 
Even if the tests for use in humans 
were successful, a vaccine would be 
of limited use, Moolten said. "The 
immune system is not inexhaustible; 
it can only make a certain number of 
antibody molecules," he said. 
"Therefore, the dose of carcinogens 
that can be neutralized by the levels 
of antibodies that animals or 
humans can reasonably be expected 
to produce is relatively small." 
The researchers are exploring the 
possibility of using "hybridomas," 
tumor lines that secrete large quanti-
ties of pure antibodies and are 
grown in the laboratory, as a source 
of antibodies against carcinogens. 
They have begun to try to establish 
hybridomas that will produce 
antibodies against PAH carcinogens, 
and others that will produce antibod-
ies against cyclic nitrosamines, 
members of another important class 
of environmental carcinogens. "The 
availability of the services of a cen-
tralized hybridoma laboratory oper-
ated by the Hubert H. Humphrey 
Cancer Research Center at BUSM 
will, we hope, facilitate these 
attempts," Moolten said. 
—Marjorie H. Dwyer 
Suggested Further Readings 
1. Moolten, F. et al.: Protection of mice against 
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skin tumors by immunization with a f luori-
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Studies show hand 
preference affects 
speech patterns 
after brain injury 
The traditional view of cerebral dom-
inance was set aside more than 30 
years ago, when scientists ascer-
tained that right- and left-handed 
people tend to have different, not 
simply reversed, kinds of brain 
organization. Recent studies on 
brain laterality at Boston University 
School of Medicine's Aphasia 
Research Center indicate that hand 
preference affects not only the way 
in which the two sides of the brain 
participate in language development, 
but also the way speech patterns 
manifest themselves after a brain 
injury. 
The Aphasia Center, which has 
been funded by the National Insti-
tutes of Health since 1965, is thought 
to be the best known and largest 
interdisciplinary research center on 
aphasia in the world. Researchers at 
the Center are devoted to the study 
of the relationship between brain 
function and language, particularly 
as it affects individuals who suffer 
aphasia (a loss of language) due to 
stroke or other brain injury, accord-
ing to Harold Goodglass, Ph.D., 
director of the Center. 
Research efforts at the Center 
range from developing treatment 
methods for patients and improved 
techniques to measure brain injury 
and language impairment to basic 
research on how the brain works. 
The work at the Center is closely 
coordinated with clinical care of 
aphasia patients at Boston Veterans 
Administration Medical Center, 
where the Center is located. 
Working under grants from the 
Veterans Administration and NIH, 
Margaret Naeser, Ph.D., an assistant 
professor in the Department of Neu-
rology at BUSM, has done research 
at the Aphasia Center that points to 
a relationship between brain shape 
and the prognosis for recovery from 
aphasia. Her work is based on an 
earlier discovery at the Center by 
Norman Geschwind, M.D., a former 
BUSM professor of neurology who 
now is at Harvard Medical School, 
that the two sides of the brain, 
although they may look alike, differ 
anatomically in size and shape in 
critical zones, most conspicuously in 
the area of language, which is larger 
on the left for most people. 
Studying computer assisted to-
mography scan (CAT-scan) pictures 
of normal and brain-injured people, 
Naeser, working with research 
assistant Jean Pieniadz, has found 
evidence that the prognosis for 
recovery from severe aphasia is 
improved for patients whose brain 
shapes don't follow the typical pat-
tern of right-handed people. Lateral 
asymmetries in the shape of the 
brain may well be genetically deter-
mined, since it is known that aphas-
ics who have a lot of left-handers in 
their families tend to recover better 
than those from exclusively right-
handed families. 
"We don't have enough data to 
make a definitive statement," said 
Goodglass, "but Dr. Naeser has had 
enough data to present it as a preli-
minary f inding." 
Although a family history of 
handedness is a useful tool in study-
ing aphasia, inheritance of handed-
ness is not a simple thing. It doesn't 
behave like a simple dominant or 
recessive gene. Studies have shown 
that the proportion of left-handed 
children produced by two left-
handed parents approaches, but 
does not exceed, 50 percent. 
"We're certain that the information 
we're gathering about brain laterality 
has useful application," said Good-
glass, who also is a professor of 
neurology at BUSM. The knowledge 
helps doctors in the diagnosis and 
prognosis of brain-injured people, 
including stroke victims, who 
account for the majority of brain 
lesion cases. 
In the early '50s, Goodglass was 
among those who did a major collec-
tion of cases of people who had lost 
their language and who were left-
handed. The research revealed that 
50 percent of the left-handers had 
their injury on the right side of the 
Aphasia Center Director Haroid Goodglass, Ph.D., stands by as research associate Jane 
Healey, Ph.D., operates a tachistoscope. The device produces precisely-controlled brief 
visual displays that may be directed to any portion of the visual field. (Photo by Bradford 
F. Herzog) 
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This CAT-scan of the human brain shows the 
longer, broader occipital pole on the left side 
of the brain (see arrow) as compared to the 
corresponding region on the right side of the 
brain. This configuration is found in most 
right-handed people. (Aphasia Research Cen-
ter photo) 
brain and 50 percent had their injury 
on the left side of the brain. 
"This means that they were not 
exceptions to the rule," explained 
Goodglass, "but that the rule that 
language is controlled by the side of 
the brain opposite your preferred 
hand simply doesn't apply to 
left-handers." 
Non-right-handers are spread over 
the spectrum of partial to total left-
hand preference, and their brain 
organization also reflects a range of 
degrees of lateral specialization. 
Nonetheless, Goodglass said no one 
has ever established a very good 
correlation between the strength of 
an individual's left-handedness and 
the probability that his or her brain 
also is very one-sided in its 
organization. 
In studying laterality, Goodglass 
pointed out, "one problem has been 
to find a way of investigating brain 
function on the two sides without 
interfering with the brain and the 
brain's operation." Early knowledge 
came from looking at patients who 
had had injuries on one side of the 
brain or the other and, in each of 
these groups, determining which 
functions were impaired. "But," he 
added, "you can't wait for patients to 
become brain-injured as your only 
source of information." 
Many techniques have been deve-
loped. Currently, Goodglass's group 
is doing experiments with the tachis-
toscopic method of lateral half-field 
presentation. It permits such infor-
mation as words, pictures or 
scrambled letters to be presented to 
one-half of the visual field at a time. 
Since anatomically, there is virtually 
a clean division right down the mid-
dle, with all information from one 
side ending up in the opposite side 
of the brain, this method makes it 
possible to differentially stimulate 
the two sides of the brain. 
When Roger Graves, Ph.D., a 
reseach associate working with 
Goodglass, used the tachistoscopic 
method to test for processing of 
emotional words, he found some-
thing that confirmed observations in 
a related area of research, which 
currently is attracting considerable 
attention. 
"When we look at right-handed 
men, we find they are solidly super-
ior in the right visual field for recog-
nizing words and solidly superior in 
the left visual field for recognizing 
faces of people and various other 
visual configurations," stated 
Goodglass. "When we look at right-
handed women, however, we find 
that they are distributed on both 
sides of their visual field with respect 
to superiority for the recognition of 
words and faces. 
"It's hard to conceive of differ-
ences in lateral brain organization as 
being cultural," he continued, 
"because you can't affect what part 
of the brain is doing what if you try. 
But it is related to the family 
handedness background, as studies 
by Jane Healey, Ph.D., a research 
associate at the Aphasia Center, 
have shown. Dr. Healey's work has 
demonstrated that a familial history 
with respect to handedness affects 
the performance of men differently 
from the way it affects the perfor-
mance of women. 
"Research findings suggest that 
women's brain laterality may be dif-
ferent from men's, but different 
primarily in the handling of input, 
that is in perception and deciding 
what has been perceived, but that it 
may not be so different in the con-
trol of speech output," Goodglass 
said. "That's an important issue 
because we know that women have 
very different performances in cer-
tain of these experiments in brain 
laterality. Women don't become 
aphasic, losing language from injur-
ies in the right side of the brain, any 
more than men do. They become 
aphasic a little less often but almost 
exclusively like men, from injuries to 
the left side of the brain." 
If women's speech production is 
lateralized like that of men, but their 
perception of written language and 
other things is differently lateralized, 
it would be important to learn about 
sex differences and lateralization. 
Indeed, one of the areas of investiga-
tion that the Aphasia Center is gear-
ing up to do is a much more inten-
sive study of how women vary 
among each other in the lateraliza-
tion of some of these functions. 
Although the research group is 
still very much interested in the psy-
chological analysis of what the left 
and right sides of the brain can do, it 
also is planning to put more effort 
into the biological implications of 
laterality. 
"It may be," Goodglass said, "that 
all these manifestations of laterality 
are simply a by-product of the action 
of a gene whose real function relates 
in an important way to reproduction, 
but which happens to influence 
handedness incidentally. We don't 
know." 
—Shirley Moskow 
Suggested Further Readings 
1. Springer, S.P. and Deutch, G.: Left Brain, 
Right Brain. Freeman, San Francisco, 1981. 
2. Segalowitz, S.J. and Gruber, F.A.: Lan-
guage, Development and Neurological 
Theory. Academic Press, 1977. 
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Diabetic retinopathy... 
continued from page 1 
the world, including nearly four mil-
lion Americans. Among the compli-
cations diabetic persons may exper-
ience are coronary artery disease, 
kidney disease, and microangio-
pathy, or small vessel disease. This 
particular vascular disorder may lead 
to diabetic retinopathy. 
"People who have had diabetes 
mellitus for a substantial period of 
time, usually 10 to 20 years, often 
are affected by diabetic retino-
pathy," explained John I. Loewen-
stein, M.D., an assistant professor of 
ophthalmology at the School of 
Medicine and co-principal investiga-
tor of the study. 
"Two types of diabetic retinopathy 
exist," he continued. "Background 
retinopathy is characterized by small 
hemorrhages and deposits in the ret-
ina. There also may be swelling in 
the area of the retina that controls 
central vision, or the macula. This 
fluid buildup can cause enough 
vision loss to constitute legal blind-
ness, but the disorder may never 
progress beyond that point. Prolifer-
ative retinopathy, the more advanced 
stage of the disease, is far more 
serious and may result in total 
blindness. 
"Microangiopathy impairs blood 
supply to the retina, depriving the 
retinal cells of oxygen, which is vital 
for proper nourishment," Loewen-
stein said. "This condition is known 
as hypoxia. The retina seems to 
respond to poor blood flow by creat-
ing new blood vessels, a process 
known as neovascularization. These 
new blood vessels are very fragile 
and can bleed or hemorrhage into 
the vitreous, the clear jelly-like sub-
stance that lies between the retina 
and the lens of the eye. This may 
cause sudden loss of vision," the 
researcher explained. "Most hemor-
rhages clear and vision returns. 
Some, however, do not, and vitreous 
surgery is required. In other cases. 
As Jonathan Teich, M.S., operates the compu-
ter terminal in the foreground, researcher Jer-
roid M. Shapiro, Ph.D., observes as fluores-
cence is detected in a patient's eye. 
the major problem is scar tissue that 
forms on the retina. When this tissue 
retracts—a normal process—it can 
pull on the retina, causing it to de-
tach. This may lead to permanent 
blindness." 
Ophthalmologists now treat prolif-
erative retinopathy with the argon 
laser in a procedure known as pan-
retinal photocoagulation. The beam 
is applied to areas of the retina 
where hypoxia is thought to exist, 
but not to the macula. By reducing 
the amount of living tissue, the 
impaired blood supply is capable of 
supporting the remaining portion of 
the retina. Although patients often 
have some constriction of their vis-
ual field and reduction of night 
vision, they can function with central 
vision and the remaining field vision. 
Further neovascularization also is 
slowed and usually reversed. 
"The laser beam is applied in a 
scattered fashion to the entire ret-
ina," said Jerrold M. Shapiro, Ph.D., 
an assistant research professor of 
ophthalmology at BUSM and co-
principal investigator for the project. 
"It's an effective treatment method, 
but some areas are needlessly coag-
ulated. Perhaps if treatment can be 
applied more selectively, less field 
vision loss will result. 
"If we can detect the exact loca-
tion of the hypoxic areas of the ret-
ina, or if we know where neovascu-
larization is about to occur," Shapiro 
continued, "then we can apply the 
laser beam exclusively to those 
areas. The procedure would be more 
selective, more effective, and would 
result in fewer side effects. Further-
more, early detection may allow 
more successful treatment and less 
vision loss." 
Because there is no animal model 
for diabetes, scientists, until now, 
have been unable to measure 
poorly-oxygenated areas of the 
human retina. "The only available 
method was highly invasive and 
involved inserting into the eye a very 
thin glass pipette with an ultra-fine 
point," Shapiro said. "This has been 
done with cats, but is inappropriate 
for humans. Any opening in the eye 
tissue invites infection, and intraocu-
lar (within the eye) infections can 
destroy the eye." 
"To accurately map hypoxic areas 
of the retina, we needed a marker in 
the eye," stated Jonathan Teich, 
M.S., a student pursuing both the 
M.D. and Ph.D. degrees at Harvard 
Medical School and Massachusetts 
Institute of Technology. He has been 
working with Loewenstein and Sha-
piro on this project for three years. 
"By measuring levels of flavin 
adenine dinucleotide, or FAD, a sub-
stance found within every retinal 
cell, the degree of hypoxia can be 
determined," Teich said. "The FAD 
molecule is fluorescent. In other 
words, it can absorb light at one 
wavelength and emit light at another 
wavelength. This fluorescence varies 
with the oxygen supply in the local 
tissue. Therefore, it acts as a marker 
for hypoxia within the cells. Previous 
indicators were outside of cells and. 
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therefore, could not be as accurate." 
"Areas on the retina with less oxy-
gen, indicating hypoxia, will f luo-
resce less." Shapiro said. "So we 
have designed and built the only 
optical scanning system that records 
retinal fluorescence." 
The unique system, which poses 
no danger to patients, includes a 
complex series of lights, lenses and 
mirrors, as well as a photomultiplier, 
which measures light, and a 
microcomputer. 
"We shine a controlled wavelength 
of light into a very small area of the 
eye," Shapiro explained. "Under 
computer control, the photomulti-
plier detects the small fluorescent 
signal. Light is then scanned across 
the eye and an image is assembled. 
The computer displays an actual pic-
ture of the area on a television 
screen, and hypoxic areas appear as 
dark spots," he said. 
"We have conducted several 
experiments with Rhesus monkeys 
that indicate a firm correlation 
between measures of fluorescence 
and retinal oxygen levels," he con-
tinued. "These have been very suc-
cessful, but animals develop only 
background retinopathy, not prolif-
erative. We are now ready to apply 
this technique to humans," Shapiro 
said. 
"We hope to evaluate diabetics 
who have different stages of diabetic 
retinopathy to determine if more 
hypoxic areas are found in people 
who are more severely diseased," 
Loewenstein added. "We also plan to 
test the theory that hypoxia pre-
cedes neovascularization. 
"Our findings should help us gain 
further insight into our understand-
ing of how the disease develops and 
progresses as well as provide the 
basis for a larger future clinical 
study," he concluded. 
Initial funding for the project was 
awarded to Shapiro in July 1979 by 
the Whitaker Health Sciences Fund. 
That $25,000 grant was presented to 
Shapiro and a collaborator from MIT 
and, according to Shapiro, was 
instrumental in financing the con-
struction of the device the BUSM 
team now uses. The National 
Society for the Prevention of Blind-
ness now supports the project with a 
one-year $9,500 grant, which will 
expire this November. 
—Susan B. Rabin 
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